News & Events

We are proud to announce that after 7 years of intensive registry work, we have reached a significant milestone: Our European Melanoma Registry now includes quality approved data from more than 25,000...

The dedicated efforts of our study centres enabled us to present our project on ‘Decision Making on Adjuvant Anti-PD-1 in Stage IIB/IIC Melanoma in Europe - Interim Analysis of DECIDE-II’ at the SMR...

We are delighted that five EUMelaReg projects had been selected to be presented at this years ESMO congress in Berlin. A special thank you to all the collaborators. Here is a short overview of our pro...

This year, our Annual Meeting took place in Berlin, just one day before ESMO. We were delighted to welcome colleagues from across Europe for an inspiring day of collaboration and discussion.

A speci...

We are delighted to inform that the EUMelaReg study "Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world eviden...

At the 11th World Congress of Melanoma and 21st EADO Congress 2025 in Athens, three EUMelaReg studies were sucessfully presented.

The two scientific poster presentations, “Single agent anti-PD-...

We are delighted to inform that another EUMelaReg study was accepted for oral presentation at the 11th World Congress of Melanoma and 21st EADO Congress, which will be held on April 3-5, 2025 in Athen...

We are proud to announce that two EUMelaReg studies were accepted for poster presentation at the 11th World Congress of Melanoma and 21st EADO Congress, which will be held on April 3-5, 2025 in Athens...

It was a great pleasure to welcome almost 60 participants to this year's meeting. We would like to thank everyone for their participation and active involvement in our recent EUMelaReg Retreat. In add...